ACADEMIA

Keio Univ. to Begin PI Trials of New Drugs for Refractory Immunological Diseases in FY2012

September 5, 2011
Keio University School of Medicine, which has been selected for a government-supported program to create “bases for early-stage and exploratory clinical research” for first-in-human clinical trials, will initiate in FY2012 a first-in-human PI clinical trial to develop a new drug…

To read the full story

ACADEMIA

By Sakura Kono

Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…

By Ken Yoshino

Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Philip Carrigan

In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…